Prime Highlights
- Mazumdar-Shaw confirmed she is the sole owner of Biocon and stressed the need to place it in capable hands before stepping back.
- The succession will be gradual, with Claire Mazumdar transitioning into the role over time rather than taking over immediately.
Key Facts
- Biocon is one of India’s largest biotechnology companies, founded by Kiran Mazumdar-Shaw. It focuses on biosimilars, biologics and research services.
- Bicara Therapeutics, led by Claire Mazumdar, is a NASDAQ-listed oncology company incubated by Biocon, currently valued at over $1.6 billion.
Background
Biocon founder and chairperson Kiran Mazumdar-Shaw has announced a formal succession plan, naming her niece Claire Mazumdar as her chosen successor to lead the biotechnology company. Mazumdar-Shaw, who founded Biocon more than four decades ago and has no children, said she believes Claire has the ability to guide the company through its next phase of growth, driven by advanced biotechnology and artificial intelligence.
Claire Mazumdar, 37, is currently the founder and CEO of Bicara Therapeutics, a NASDAQ-listed company incubated by Biocon with a market capitalisation of over $1.6 billion. She holds degrees from MIT and Stanford, including a PhD in cancer biology, and has previously worked with Third Rock Ventures and Rheos Medicines. Bicara was listed in 2024.
Mazumdar-Shaw said the transition would be gradual, indicating she was not stepping down immediately and that Claire would move into her role over time. She stressed the importance of placing the company in capable hands, given that she is its sole owner.
The broader family ecosystem is also expected to support Biocon’s future. Claire’s brother Eric Mazumdar, a Caltech professor and AI expert, and her husband Thomas Roberts, an oncologist at Massachusetts General Hospital, form part of that network.
Biocon has also undergone structural changes, merging its generics and biologics businesses and reducing debt. At present, biosimilars contribute to 60% of their sales, with 12 drugs on offer and 20 other products moving towards market launch. Changes in leadership are also taking place in some group companies, including new CEOs at Biocon Biologics and Syngene International.
